Literature DB >> 3156668

In vitro selective effect of melphalan on human T-cell populations.

S Ben-Efraim, L Komlos, J Notmann, J Hart, I Halbrecht.   

Abstract

In vitro treatment with 2 micrograms/2 X 10(6) cells melphalan (L-PAM: L-phenylalanine mustard) significantly decreased the total number of T lymphocytes from peripheral blood (PBL) of healthy human donors and of the OKT4 population (precursor suppressor/helper/inducer) T cells as defined by monoclonal antibodies OKT3 and OKT4, respectively. No changes in the OKT+8 lymphocyte population (cytotoxic/mature suppressor cells) were observed following the same treatment. Preincubation of PBL with L-PAM at concentrations that do not affect the rate of DNA synthesis in PHA-stimulated lymphocytes inhibited the generation of T suppressor lymphocytes by ConA, as shown by their effect on PHA stimulation. Treatment of allogeneic PBL with L-PAM had no effect on mature suppressor T cells already induced by ConA, as shown by incubation of PBL with L-PAM after incubation with ConA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156668     DOI: 10.1007/bf00199312

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Melphalan adjuvant therapy in breast cancer.

Authors:  J T Carpenter; W A Maddox
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

3.  Functional analysis of human T cell subsets defined by monoclonal antibodies. V. Suppressor cells within the activated OKT4+ population belong to a distinct subset.

Authors:  Y Thomas; L Rogozinski; O H Irigoyen; H H Shen; M A Talle; G Goldstein; L Chess
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

4.  In vitro effects of 4-hydroperoxycyclophosphamide on concanavalin A-induced human suppressor T cells.

Authors:  A Klajman; I Drucker; Y Manor; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

Authors:  T J McElwain; R L Powles
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

7.  In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration.

Authors:  H Ozer; J W Cowens; M Colvin; A Nussbaum-Blumenson; D Sheedy
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

8.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

9.  Analysis of synergy between cyclophosphamide therapy and immunity against a mouse tumour.

Authors:  D M Chassoux; F M Gotch; I C MacLennan
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

10.  Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.

Authors:  M A Cornbleet; T J McElwain; P J Kumar; J Filshie; P Selby; R L Carter; D W Hedley; M L Clark; J L Millar
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

View more
  3 in total

1.  Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.

Authors:  S Nanbara; S Arinaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Effect of melphalan in vitro on induction of murine suppressor T cells by ConA.

Authors:  R Ophir; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.

Authors:  S Ben-Efraim; S Shoval; R Ophir
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.